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Abstract Study Objectives:Penicillinresistancehasbeenreportedinvarious studies tohaveno impactonthe outcome
of pneumococcalpneumonia.However, the importance of cephalosporinresistancehasnotbeen systematically studied.
We conducted an analysis of patients with high-level cephalosporin-resistant Streptococcus pneumoniae pneumonia (H-
CRSPP)^Design:Retrospectivematched, case^control study. Setting:Two inner-city academic hospitals.Patients:Twenty-
six patients with H-CRSPP admitted to the hospital between1995 and1999 were identi¢ed.Each patient was matched
with two controls with cephalosporin-sensitive but oxacillin-resistant pneumococcal pneumonia admitted during the
same time period.Matchingwas done based onpneumonia severityof illness index (PSI) and for other factors. Interven-
tions:None. Measurements and Results:We evaluated a number of outcomes including mortality, length of stay in the
hospital, and time to respond to treatment.Patientswith H-CRSPP took longer to respond to treatment (6.570.9 days
vs 4.170.7 days, P¼0.05) and had a longer length of stay in hospital (15.472.2 days vs 9.271.6 days, P¼0.02),None of the
otheroutcomeswere di¡erentbetweenthetwogroups.Conclusions:Overall, wehave foundthatthepresence ofcepha-
losporin resistance does impactthe course of pneumococcalpneumonia.r2002 Elsevier Science Ltd.Allrights reserved
doi:10.1053/rmed.2002.1358, available online at http://www.idealibrary.comon
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Pneumonia is the sixth leading cause of death in the U.S.
and is themost common cause of infection-relatedmor-
tality (1). Streptococcus pneumoniae continues to be the
leading cause of adult community-acquired pneumonia
(CAP), accounting for approximately 30% of episodes
(2). Penicillin-resistant strains of pneumococcal pneumo-
niae were ¢rst described 30 years ago (3). Since then,
there has been a worldwide phenomenon of increasing
resistance to penicillin andmultiple other antibiotics, in-
cluding cephalosporins (4).
Alongwith the emergence of this resistance, therehas
been an increased interest in the clinical sequelae of
infection with these organisms. The ¢rst look at the
problem came from Spain (5). Pallares and colleagues fol-
lowed 504 patients with S. pneumoniae pneumonia,116 of
whom had penicillin-resistant S. pneumoniae (PRSP) and
29 patients had cephalosporin-resistant S. pneumoniaeReceived10 December 2001, accepted in revised form1April 2002.
Correspondence should be addressed to:Dr.Bruno DiGiovine,MD,
Department of Pulmonary and Critical Care Medicine,Henry Ford
Hospital, 2799WGrand Boulevard, K-17,Detroit,Michigan 48202,
U.S.A.Fax: +313 916 9102; E-mail: bdigiovl@hfhs.org(CRSP).They found no excess mortality in patients with
penicillin or cephalosporin-resistance. The other large
study looking at PRSP and CRSP involved 49 patients
with PRSP and 31 patients with CRSP (6). In this study,
the authors concluded thatdrugresistance didnot a¡ect
the outcome. Two recent papers have re-looked at the
issue of outcome in patients with drug-resistant pneu-
mococcus (7,8). In a study by Metlay and colleagues, pre-
sence of penicillin resistance did show increased risk of
suppurative outcomes (8). In a large surveillance study
by Feikin and colleagues, presence of extremely high-le-
vel penicillin resistance (minimal inhibitory concentra-
tion (MIC)X4.0) was found to be a risk factor for in-
hospitalmortality, after excludingpatientswho died dur-
ing the¢rst4daysof thestudy.Also,high-level(MICX2.0)
resistance to cefotaxime but not penicillin was asso-
ciatedwith late hospital deaths (7).
We wanted to determine if high-level cephalosporin
resistance a¡ected the outcome of hospitalized patients
with pneumococcal pneumonia. We felt that mortality
alone would be an insensitive outcome measure.There-
fore, we looked at ¢ve other outcomes in patients
with high-level cephalosporin-resistant pneumococcal
pneumonia (H-CRSPP): (1) length of stay (LOS) in the
hospital; (2) LOS in the intensive care unit; (3) number
TABLE 1. Matchingcriteria
Characteristic Points
Pneumonia score710 10
720 5
Age710 5
Sexmatch 5
Yearof admission72 3
Presence of penicillin resistance inthe control 3
Matching of bacteremia 2
Match of COPD 1
Diabetesmellitus 1
806 RESPIRATORYMEDICINEof antibiotics used during the hospital stay; (4) time to
respond to therapy; and (5) failure of primary therapy.
METHODS
The ethics committees of our institutions approved the
study protocol. Potential isolates were found by review-
ing the records of the microbiology departments of
Henry Ford Hospital (HFH) and the Detroit Medical
Center (DMC) between 1993 and October 1999. Initial
susceptibility to penicillin was tested by oxacillin disk
di¡usion test. Isolates resistant to oxacillin disk
di¡usion test were further evaluated by E-test with
susceptibility breakpoints de¢ned according to the Na-
tional Committee for Clinical Laboratory Standards
(NCCLS) guidelines (9,10). A pneumococcal isolate was
considered susceptible to penicillin if the MIC was
r0.06mg/ml, to be of intermediate resistance if the MIC
was between 0.12 and 1mg/ml, to be highly resistant if
the MIC was 2.0mg/ml. The pneumococcal isolate
was considered susceptible to cephalosporins if the MIC
was r0.5mg/ml, to be of intermediate resistance if
the MIC was 1mg/ml, to be highly resistant if the MIC
was2.0mg/ml.
Records of all adult patients (age418 years) with po-
sitive S. pneumoniae cultures from blood, sputum, or
bronchoalveolar lavage (BAL) were then reviewed. Pa-
tients were de¢ned to have pneumonia if they had (1) a
new pulmonary opacity compatible with pneumonia on
chest radiograph and con¢rmed by a radiologist; and (2)
1 or more signs and symptoms consistent with a lower
respiratory tract infection, including temperatures
greater than 381C, new or increased cough, production
of purulent sputum, crackles, rhonchi, or pleuritic chest
pain or dyspnea; or (3) an elevated white blood cell
count (410109/L) or greater than 0.15 band forms. Pa-
tientswere excluded if theymet one of the following cri-
teria: age o18 years; isolation of S. pneumoniae on a
culture taken more than 3 days after admission; lack of
admission to the hospital; transfer from another hospi-
tal; patients with3 of the19 possible pieces of data for
the pneumonia severity index missing; previously en-
rolled patient.Cases were de¢ned as patients with MIC
2.0 g/ml to cefotaxime.Controls were selected among
patients with CAP who met the inclusion criteria and
were infectedwith S. pneumoniae sensitive to cefotaxime
(MICr0.5) butresistant to oxacillin (20mmzone of in-
hibition).
Pneumonia severity was assessed by means of the
pneumonia severity of illness index (PSI) (11,12). The
PSI is a validated disease severity classi¢cation based
upon a number of factors (11,12). A PSI score was calcu-
lated for all potential cases and controls.The data to cal-
culate these scores and obtain other potential
information were obtained via chart review. Results ofthe initial laboratory tests done in the emergency de-
partment (ED) were used for scoring. In patients who
did not have a particular test done in the ED, the ¢rst
test results obtained after admission were used for the
study. In cases of missing data, the variables were pre-
sumed to be normal. However, if three or more of the
19 data points needed to compute the PSI were missing
for any one patient, that patient was excluded from
further study.
Each case was matched to two controls by one of the
investigators (BD) who was blinded to the clinical out-
come of the patients. Cases from each institution were
matchedwith controls from the same institution.Match-
ing was based upon age, sex, PSI, year of admission, and
other factors listed inTable 1. This method of matching
has been usedwith good e¡ect in previous studies inves-
tigating the attributable mortality and morbidity of no-
socomial bacteremia (13,14). Although all the controls
were oxacillin resistant, all were not resistant to penicil-
lin. When matching, attempt was made to include pa-
tients with penicillin resistance as controls. The relative
importance of the matching criteria is outlined inTable
1.The scoring system shownwas derivedprior tomatch-
ing andwas arrived atbasedupon a clinical impression of
the relative importance of each factor, as has been done
previously (13). This scoring system allowed us to assess
the adequacy of matching by calculating a match score,
with the best possible score of 30 points.
A data collection form was used to collect the out-
come information from the medical record. The out-
comes of interest were: (1) hospital mortality; (2) LOS
in the hospital; (3) LOS in the intensive care unit; (4)
number of antibiotics used during the hospital stay; (5)
time to respond to therapy; and (6) failure of primary
therapy.
The criterion of time to respondwas developedbased
on a prior study looking at the validity of this measure
(15).Response to therapy was de¢ned as resolution of fe-
ver (temperature consistently less than 381C), respira-
tory rate consistently less than 24, improvement of
symptoms of pneumonia (as noted by the physician
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bility of abnormalities on radiograph. The respiratory
rate and temperature had to be in the appropriate range
for at least 48h before response could be said to have
occurred. In terms of radiographic stability, the radio-
graph was considered to be stable unless there was a
radiograph done which showed worsening. In patients
on mechanical ventilation, the time to respond was de-
¢ned as the day the patient had satis¢ed all of the above
criteria andwas extubated. In patients dischargedbefore
48hwere over, itwaspresumed that thepatients didnot
have anyrecurrence of symptoms.The time (in days) that
it took for this to occur was de¢ned as the time to re-
spond. If the patient died without ever developing a clin-
ical response, they were excluded from further analysis
on this variable although they were counted as failure of
primary therapy (see below).
Failure of primary therapy was de¢ned as the occur-
rence in one of the two ways. Either the patient had to
show a lack of response (as discussed above) despite
greater than 72h of therapy or the patient had evidence
of worsening on therapy as shown by a need for intuba-
tion or death after at least 24h of therapy.
Statistical analysis
All the statistical tests were done after accounting for
the matched design of the study. Continuous outcome
variables were compared using a paired t-test.
Demographic continuous data were reported as the
mean7standard deviation. Continuous data that were
obtained by comparing the two groups were reported
as a least-square mean7standard error. Categorical
variables were compared using conditional logistic re-
gression. Because of the potential importance of PSI in
predicting outcomes, we analyzed outcomes after con-
trolling for PSI, even though it was a matching variable
(16).We also controlled for age, sex and year of admission
where it was appropriate.That is, we evaluated the sig-
ni¢cance of these variables in each model.When the P
value for the variable wasr0.10, it was left in the ¢nal
model. All the analyseswere donewith Statistical Analy-
sis Software Package (SAS Institute,Cary, NC,U.S.A). In
all instances, an alpha level of 0.05 was used to decide
whether the null hypothesis of no di¡erence between
the two groups could be rejected.
RESULTS
From1995 to 1999, a total of 3033 isolates of S. pneumo-
niaewere found in blood, sputum or BAL £uid in themi-
crobiology laboratories of HFH and DMC.Of the 3033
isolates, 664 (21.9%) were oxacillin resistant.Three hun-
dred and nineteen isolates (10.5%) had intermediate re-
sistance and 135 isolates (4.5%) had high-level resistanceto penicillin. One hundred and eleven (3.7%) isolates
were found to have intermediate resistance to cephalos-
porins and 54 (1.8%) isolates had high-level resistance to
cephalosporins. Of the 54 isolates with high-level resis-
tance to cephalosporins, 21hadmultiple drug resistance,
i.e. resistance to two other antibiotic groups in addition
to penicillin and cephalosporins. Thirteen patients were
excludeddue to ageo18 years,12 patientswere excluded
as the patients did not have pneumonia, two patients
were excluded as the patients were not admitted to the
hospital and one patient was admitted twice for H-
CRSPP.Thus, we had 26 cases.
For each case, we chose two controls.These controls
were chosen from a group of 121patients (62 from HFH
and 59 from DMC) who had CAP due to S. pneumonia
resistant to oxacillin but sensitive to cefotaxime. Cases
and controls were similar and there was no statistically
signi¢cant di¡erence between the two groups except
that more patients in the case group presented with
dyspnea (Table 2). Of the 52 controls matched with
the cases, 37 (71%) were resistant to penicillin and the
rest were resistant to oxacillin disk, but sensitive to
penicillin.
The average PSI scoreswere similar in the two groups.
Also, the percentage of patients in the highest risk class,
IV and V, was similar in the two groups (43% vs. 44%,
P¼1.00). Matching scores were 25.272.9 (range 17^30,
median 25) for the patients from Henry Ford Hospital
and 24.173.8 (range 19^30, median 24.5) for patients
from Detroit Medical Center. In 41 out of 52 matches,
the patients were matched within 710 points for PSI
score.Given the fact that we were able to match within
10 points only 79% of the time, we adjusted for PSI in
evaluating outcomes for all of the subjects. In other
words, we included PSI in all of our ¢nal multivariate re-
gressions so as to decrease the potential for it to con-
found the relationship between the presence of H-
CRSPP and the outcomes of interest.
The treatment regimens used initially in the two
groups are shown inTable 3. There was no di¡erence in
these regimens. After adjusting for age, sex, PSI, year of
admission and presence of bacteremia, we found no dif-
ference in mortality, number of patients intubated, ICU
admission rates or the number of antibiotics used be-
tween the two groups (Table 4). No patient was read-
mitted within the1month of discharge, but there was a
trend towards patients with H-CRSPP being more likely
to fail treatment (27 vs12%, P¼0.10; RR¼2.9 (0.82,10)). In
addition, vancomycin was used more often in the case
group (50 vs15%, P¼0.001; RR¼ 3.25 (1.59, 6.65)).
In terms of failure of primary therapy, there was no
statistical di¡erence in the mode of failure with the ma-
jority of patients failing because of worsening after 24h
of therapy (5/7 of the cases and 4/6 of the controls).
When further evaluating failure of primary therapy,
one might be interested in whether the initial antibiotic
TABLE 2. Characteristics of case and controlgroups
Patientcharacteristics Cases
(n¼26)
Controls
(n¼52)
P value
Demographics
Mean age (years)7SD 53717.5 53.4718.4 0.92
Males 18 (69%) 30 (58%) 0.46
Co-existing conditions
Meanco-morbid illness per patient 0.85 0.83 1.0
Use of intravenous drugs 6 (23%) 7 (13%) 0.45
Total immunocompromised 6 (23%) 12 (23%) 1.0
Non-HIV 4 (15%) 9 (17%)
HIV 2 (8%) 3 (6%)
Bacteremia 8 (31%) 21 (40%) 0.56
Active smokers 14 (54%) 25 (48%) 0.81
Current alcoholuse 10 (38%) 18 (35%) 0.93
Symptoms
Cough 23 (88%) 42 (81%) 0.59
Chest pain 14 (54%) 23 (44%) 0.57
Dyspnea 19 (73%) 23 (44%) 0.03
Fever 20 (77%) 36 (69%) 0.66
Physical examination ¢ndings
Alteredmental status 3 (12%) 12 (23%) 0.36
PulseX125/min 7 (27%) 12 (23%) 0.93
RespiratoryrateX30/min 7 (27%) 11 (21%) 0.78
Systolic bloodpressureo90mmHg 6 (23%) 4 (8%) 0.12
Tempo351CorX401C 2 (8%) 3 (6%) 1.0
Laboratory andradiological ¢ndings
Bloodurea nitrogenX30mg/dl 5 (19%) 12 (23%) 0.92
GlucoseX250mg/dl 0 (0%) 4 (8%) 0.36
Hematocrito30% 2 (8%) 4 (8%) 1.0
Sodiumo130mmol/l 2 (8%) 6 (12%) 0.90
Oxygen sato90 or PaO2o60mmHg 11 (42%) 18 (35%) 0.68
ArterialpHo7.35 1 (4%) 8 (15%) 0.26
Pleural e¡usion 9 (35%) 12 (23%) 0.42
Multilobar pneumonia 9 (35%) 16 (31%) 0.93
Initial treatment
Mean7 SDhours for ¢rst antibiotic dose 10.7713.4 8.176.5 0.38
Patientswho received dosewithin 8 h 14 (54%) 32 (62%) 0.44
Patients intubated in the ED 3 (12%) 10 (19%) 0.59
Mean PSI7SD 89744 91743 0.91
Risk Class IVand Va 11 (42%) 23 (44%) 1.00
aRiskclass based on Pneumonia Severity Indexof Illness calculations atthe time of admission (15,16).
TABLE 3. Initial antibiotic regimens aswell as rate of treatment failure for the regimen
Initial antibiotic regimen Cases (26) Controls (52) Failure rate
Secondgeneration cephalosporins7macrolide 10 (38%) 17 (33%) 18.5%
Vancomycin7anyotherdrag 4 (15%) 5 (10%) 0%
Third-generation cephalosporins7macrolide 2 (8%) 6 (12%) 12.5%
Co-trimoxazole and ormacrolide 5 (19%) 13 (25%) 22.2%
Penicillin G 1 (4%) 4 (8%) 0%
Co-trimoxazole+second-generation cephalosporins 0 (0%) 4 (8%) 25%
Others 4 (15%) 3 (6%) 28.6%
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TABLE 4. Outcomesin case and controlgroups
Outcome Cases (26) Controls (52) P value
Death 1 (4%) 3 (6%) 1.0
Failed treatment 7 (27%) 6 (12%) 0.10
Meannumberof antibiotics7SD 3.472.1 2.972 0.16
Patients admitted to the ICU 10 (38%) 15 (29%) 0.18
Vancomycinuse 13 (50%) 8 (15%) 0.003
FIG. 1. Length of stay and time to respond (mean7standard error) after adjusting for PSI, age, and year of admission in the case and
controlgroups.
CEPHALOSPORIN-RESISTANTPNEUMOCOCCALPNEUMONIA 809regimenwas independently associatedwith likelihood of
failure.The slight di¡erences in failure rates shown in Ta-
ble 3 were not signi¢cantly di¡erent (P¼0.64). Most im-
portantly, therewas no evidence that antibiotic choice in
any way confounded the relationship between cephalos-
porin resistance and outcome. Also, these outcomes
werenotdue to extremelyhigh-levelpenicillin resistance
(MIC4.0) as only four of the cases had such levels.
Themain di¡erences in outcome arenotedwhen look-
ing at the time to respond to therapy and length of stay
in the hospital. After controlling for year of admission,
cases took, on average, 2.4 more days to respond
(6.570.9 vs 4.170.7, P¼0.05; 95% CI for di¡erence: (0.1,
4.7)) (Fig. 1). Also, after controlling for age and year ofadmission, they were in the hospital for a mean of 6.2
more days (15.472.2 vs 9.271.6, P¼0.02; 95% CI for dif-
ference: (0.9, 11.5)) (Fig. 1). They seemed to have a 5 day
longer LOS in the ICU, although thiswas not quite statis-
tically signi¢cant (8.172.1vs 3.171.5, P¼0.07; 95% CI for
di¡erence: (0.3,10.3)).
DISCUSSION
In this case^ control study, we found that patients with
H-CRSPP took longer to respond to therapy and have a
longer length of stay.We also found that the likelihood
of failing primary therapy was higher in these patients.
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are notable, in particular, because of their di¡erence
from themajor previous studies (5,6).
A review of the prior studies may help point out po-
tential reasons for the di¡erences in results (5,6). Prior
studies included only a small number of patients with
high-level cephalosporin resistance (four patients in the
Pallares study and nine patients in the Ewig study).
Therefore, their studieswere likely underpowered espe-
cially given that the main outcome they looked at was
mortality. In fact, we toowereunable to ¢nd a di¡erence
in mortality as our study also lacked the power to ade-
quately evaluate this end point. However, by examining
factors such as length of stay in the hospital and time to
respond to treatment, wewere able to show di¡erences
between the two groups.Our study is the ¢rst study to
show that patients with H-CRSPP have a highermorbid-
ity.
The importance of this increased length of stay canbe
appreciated when one considers the costs of treating
CAP. Recent national data suggest that each day in the
hospital for the treatment of pneumonia costs approxi-
mately $1027 (17). Therefore, 6.4 extra days would cost
$6 573 per patient of H-CRSPP. From 1988 to 1994, the
average number of patients admitted yearly for CAP
has been 1.135 million (17). Given that S. pneumoniae ac-
counts for 30% of all causes of CAP and the prevalence
of high-level cephalosporin-resistant pneumococcus is
4% (12,18), the number of patients with H-CRSPP will be
13,620 per year. Therefore, the excess costs associated
with these infections would be close to $90 million per
year.
Since mortality is a relatively uncommon end point in
CAP,weused length of stay and othermarkers like‘‘time
to respond to therapy’’ and ‘‘failure of primary treat-
ment’’ to indicate poor outcomes. The end points of
‘‘time to respond to therapy’’ and ‘‘failure of primary
treatment’’ could be questioned because they involve
subjective criteria. Nevertheless, these outcomes were
based on previous studies and/or obvious clinical end
points.The criterion of time to respond was developed
based on a study looking at ‘‘time to resolution of mor-
bidity’’ (TRM) in100 patientswith pneumonia (15). In that
study, TRM had been found to correlate better with
length of stay than APACHE II.Onemight be concerned
that time torespondcouldbe overly a¡ectedbywhether
the patients were intubated in the ED as patients had to
be extubated to be considered to have responded to
therapy. Although this is a reasonable concern, it did
not in£uence our results as a greater percentage of the
controls in this study were intubated in the ED (19 vs
12%).
The other subjective criterionusedwas ‘‘failure of pri-
mary treatment.’’ We developed this criterion for the
study and there have been no papers looking into this
or a similar outcome. As in the case of ‘‘time torespond,’’we had fairly well-de¢ned criteria for this outcome.
Though we used subjective end points, based on the
above discussion, we think these end points are valid.
Another potential limitation of our study is the
matched case^ control design. The validity of any
matched case^ control study is limited by the strength
of thematching and the appropriateness of thematching
criteria. In this study, we matched for PSI, age, sex, year
of admission, presence of resistance to penicillin, pre-
sence of bacteremia, presence of chronic obstructive
pulmonary disease and diabetes mellitus. Except for the
studybyMetlay and colleagues, none of the previous stu-
dies on this subject controlled for severity of illness on
presentation (5^8). An important factor to consider in
comparing outcomesbetween two groupswith a disease
entity is to make sure that the patients have similar se-
verity of illness (16). This is especially true when investi-
gating resistance, as thepresence of a resistant organism
may be a marker for a more severe disease.We there-
fore used PSI score to control pneumonia severity of ill-
ness in the design and analysis of this study as this score
has been validated in over 50,000 patients (12).
Another limitation of our study is that, as itwas retro-
spective, we could not control the therapy that was ad-
ministered. Systematic di¡erences in treatment based
upon the organisms’ sensitivities could have biased the
study. In fact, we did show that the groupwith H-CRSPP
did receive more vancomycin than the comparison
group. Although this could suggest that this group was
sicker, we feel that this is in fact a re£ection of the sensi-
tivity patterns as 62% of the cases who received vanco-
mycin did so only after the sensitivities were reported.
More importantly, this di¡erence in treatment could
have led to us ¢nding less of a di¡erence between groups
than would have been shown if they received similar
treatments. As such, our estimate of themorbidity asso-
ciatedwith H-CRSPP may be conservative.
A reevaluation of empiric therapy for CAP is war-
ranted in the light of our ¢ndings that H-CRSPP is asso-
ciated with increased morbidity. Current guidelines
recommend empiric therapy for hospitalized patients
with CAP with either a third-generation cephalosporin
plus a macrolide or a £uoroquinolone (19).Given the fact
that the morbidity seen in our patients with H-CRSPP
was not severe, we would not recommend a change in
these empiric recommendations based upon our data.
However, if the prevalence of high-level cephalosporin
resistance in a community is elevated (45%), one might
consider empiric treatment with a quinolone as there
does not seem to be a correlationbetween cephalospor-
in resistance andquinoloneresistance (20,21). Also, inpa-
tients with documented H-CRSPP, antibiotic therapy
should be tailored to their sensitivity pattern.
In summary, we feel that our results are not invali-
dated by any potential limitations. As such, we can con-
clude that patients with H-CRSPP take longer to
CEPHALOSPORIN-RESISTANTPNEUMOCOCCALPNEUMONIA 811respond to therapy and have a longer length of stay.
These di¡erences in the course of H-CRSPP are impor-
tant as they can be translated into excess costs of close
to $$90 million in the U.S. Larger prospective studies
looking at the risk factors for H-CRSPP and impact of
early intervention in patients at risk for H-CRSPP are
needed.
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